Literature DB >> 8061013

Infection after heart transplantation: a multiinstitutional study. Cardiac Transplant Research Database Group.

L W Miller1, D C Naftel, R C Bourge, J K Kirklin, S C Brozena, J Jarcho, R E Hobbs, R M Mills.   

Abstract

The incidence, causes, and impact of acute infection were analyzed among 814 consecutive patients from 24 institutions undergoing primary heart transplantation between January 1, 1990, and June 30, 1991, with mean follow-up of 8.2 months (range 0 to 18 months). Sixty-nine percent of the patients had no infections during the follow-up, whereas 31% of patients had one or more infection episodes. The cumulative incidence of infections per patient was 0.41 at 3 months, 0.55 at 6 months, and 0.62 at 12 months after transplantation. Bacterial and viral infections were most common (47% and 41% of infections), with fungi and protozoa accounting for 12%. Overall mortality per infection was 13%, but mortality with fungal infections was higher (36%, p < 0.0001). The most common organ infected was the lung, with a mortality of 23%. The probability of infection by 12 months was higher when OKT3 or antithymocyte globulin induction therapy was used (41% versus 35%, p = 0.01). The single most frequent infecting organism was cytomegalovirus, accounting for 26% of all infections. The probability of cytomegalovirus infection by 12 months was increased with a cytomegalovirus-positive donor and cytomegalovirus-negative recipient (27% versus 15% in all others, p < 0.0001) and with the use of OKT3 or antithymocyte globulin induction therapy (19% versus 12% without induction therapy, p = 0.07). Infection remains the leading cause of death after heart transplantation. The hazard function of likelihood of developing each type of infection at various times after transplantation, as well as response to therapy, are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061013

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

1.  Hamilton Naki, transplant surgeon.

Authors:  Chike M Nzerue
Journal:  J Natl Med Assoc       Date:  2006-03       Impact factor: 1.798

2.  Cardiac transplantation for pediatric patients. With inoperable congenital heart disease.

Authors:  K M Shaffer; S W Denfield; K O Schowengerdt; J A Towbin; B Radovancević; O H Frazier; J K Price; R J Gajarski
Journal:  Tex Heart Inst J       Date:  1998

3.  Open-chest management after heart transplantation.

Authors:  Hiroo Takayama; Richard J Leone; Gabriel S Aldea; Daniel P Fishbein; Edward D Verrier; Christopher T Salerno
Journal:  Tex Heart Inst J       Date:  2006

4.  Limb Ischemia after Heart Transplantation: An Unusual Case of Tissue Embolism.

Authors:  Seyed Mohsen Mirhosseini; Ali Sanjari Moghaddam
Journal:  J Tehran Heart Cent       Date:  2017-04

Review 5.  [Preventive antimycotic therapy of neutropenic and immunosuppressed patients].

Authors:  M Ruhnke; J Beyer
Journal:  Med Klin (Munich)       Date:  1997-01-15

Review 6.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 7.  Fungal infections: a growing threat.

Authors:  D M Dixon; M M McNeil; M L Cohen; B G Gellin; J R La Montagne
Journal:  Public Health Rep       Date:  1996 May-Jun       Impact factor: 2.792

8.  Heart transplantation for dilated cardiomyopathy.

Authors:  S S Adwani; B F Whitehead; P G Rees; P Whitmore; J W Fabre; M J Elliott; M R de Leval
Journal:  Arch Dis Child       Date:  1995-11       Impact factor: 3.791

9.  Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study.

Authors:  M Winkler; J Pratschke; U Schulz; S Zheng; M Zhang; W Li; M Lu; D Sgarabotto; G Sganga; P Kaskel; S Chandwani; L Ma; J Petrovic; M Shivaprakash
Journal:  Transpl Infect Dis       Date:  2010-01-11       Impact factor: 2.228

10.  A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation.

Authors:  John C Mullen; Emily J Kuurstra; Antigone Oreopoulos; Michael J Bentley; Shaohua Wang
Journal:  Transplant Res       Date:  2014-07-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.